News for Incyte Corporation (I1NC34.SA)

Incyte (Nasdaq:INCY) today announced results from its pivotal Phase 3 TRuE-PN clinical trial program ”“TRuE-PN1 and TRuE-PN2 studies ”“ evaluating the safety

- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC

**media[552869]**

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health …

Operator: Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode.

Incyte Corporation (NASDAQ:INCY) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ETCompany ParticipantsBen Strain - Associate Vice President,...

The following slide deck was published by Incyte Corporation in conjunction with their 2024 Q4 earnings call.

Incyte Corporation (INCY) has announced a significant change in its executive leadership team. On January 6, 2025, Barry P. Flannelly, who has served as the E

The Indian stock markets have experienced a downturn since late September 2024. However, some stocks defied the trend. Read on to know more about these resilient stocks that have consistently beaten earnings estimates.

Incyte (Nasdaq:INCY) today announced results from the Phase 3 POD1UM-304 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed

With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future of artificial intelligence, the Federal Reserve’s interest rate cut cycle, and an economy with ...

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28%

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday. The Dow traded down 0.03% to 43,374.79 while the...

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Tuesday. Shares of AECOM ACM fell sharply in today's pre-marke...

Incyte Corporation (INCY) shares plunged 11.26% on Tuesday and here are some significant developments recently:Pipeline ChallengesIncyte has had some problems w

Shares of Symbotic Inc. SYM rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Symbot...

The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033.

The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by various factors, as well as...

The allogeneic hematopoietic stem cell transplant market is expected to experience significant growth in the coming years, driven by advances in...